AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
X-ray analysis conducted on protein vaccine candidate for malaria.
2004 JUN 2 - (NewsRx.com & NewsRx.net) -- Scientists have conducted a preliminary X-ray analysis of the Plasmodium vivax sexual stage 25-kDa protein Pvs25, a transmission-blocking vaccine candidate for malaria.
According to a study from the United States, "The Plasmodium vivax sexual stage 25-kDa protein Pvs25 is expressed on the surface of the ookinete form of the parasite. Monoclonal antibodies directed against Pvs25 block the development of P. vivax oocysts in the mosquito host. Thus, Pvs25 is a potential vaccine candidate for eliciting transmission-blocking immunity in individuals living in malaria-epidemic regions.
"Pvs25 which was expressed and purified for clinical trials was crystallized using polyethylene glycol as the precipitating agent and diffracts X-rays to 2.3 angstrom," said A. K. Saxena and colleagues at the National Institute of Allergy and Infectious Diseases. "The orthorhombic Pvs25 crystal form belongs to space group P2[subscript]12[subscript]12[subscript]1, with unit-cell parameters a=42.6, b=59.8, c=66.8 angstrom and one molecule in the asymmetric unit.
"Reductively methylated Pvs25 crystallized in two forms: an orthorhombic P2[subscript]12[subscript]12[subscript]1 form with unit-cell parameters a=43.4, b=62.9, c=66.9 Angstrom and one molecule in the asymmetric unit and a monoclinic P2[subscript]1 form with unit-cell parameters a=53.5, b=43.3, c=65.3 angstrom, beta=104.0 degrees ...
- VaxGen Awarded $80.3 Million NIAID Contract for Advanced Development of Anthrax...
- Press release article from: PR Newswire October 1, 2003 700+ words
...3 million contract from the National Institute of Allergy and Infectious Diseases...development of its anthrax vaccine candidate, rPA102. The 3-year contract...with Federal funds from the National Institute of Allergy and Infectious Diseases...
- VaxGen awarded $80.3 M NIAID contract for advanced development of anthrax...
- News wire article from: Asia Africa Intelligence Wire September 30, 2003 700+ words
...awarded an $80.3 M contract from the National Institute of Allergy and Infectious Diseases...advanced development of its anthrax vaccine candidate, rPA102. The 3-year contract...required for commercial licensure of the vaccine candidate and could pave the way for a significantly...
- Chiron's HIV Vaccine Candidate Begins Clinical Trial in United States; Trial...
- Press release article from: PR Newswire January 15, 2004 700+ words
...States for its HIV vaccine candidate. The trial, the...funded by the National Institute of Allergy and...Chiron's vaccine candidate represents a novel...health." The vaccine candidate employs a strategy...
- Chiron's HIV vaccine candidate begins clinical trial in US.
- News wire article from: Asia Africa Intelligence Wire January 15, 2004 700+ words
...trial in the US for its HIV vaccine candidate. The trial, the result...HVTN), funded by the National Institute of Allergy and Infectious...immunogenicity of the vaccine. The vaccine candidate employs a strategy that involves...
- Merck's Investigational HIV/AIDS Vaccine Candidate Advances To Phase II...
- Press release article from: Business Wire January 24, 2005 700+ words
...Efficacy Test of Merck Vaccine Candidate The HIV Vaccine...HVTN, and the National Institute of Allergy and...the HVTN. The vaccine candidate used in this study...concept that the vaccine candidate prevents HIV infection...
- Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax...
- Press release article from: Business Wire May 5, 2008 700+ words
...About rPA 102 The vaccine candidate, rPA 102, is...anthrax toxins. The vaccine candidate does not cause...million from the National Institute for Allergy and...clinical trial of the vaccine candidate by December 18...
- Merck's Investigational HIV Vaccine Candidate to be Studied In Collaborative...
- Press release article from: Business Wire September 19, 2003 700+ words
...of Merck's HIV vaccine candidate in 18 cities around...study of an HIV vaccine candidate to take place in...supported by the National Institute of Allergy and...investigational HIV vaccine candidate on a truly global...
- FDA Clears VaxGen's IND for Anthrax Vaccine Candidate; Clinical Development to...
- Press release article from: PR Newswire May 27, 2003 700+ words
...anthrax vaccine. The vaccine candidate's efficacy will be established...AI-25494, with the National Institute of Allergy and Infectious...development of an rPA anthrax vaccine candidate. Deliverables under this...intends to produce the vaccine candidate at its ...
- South Africa Approves IAVI Sponsored AIDS Vaccine Candidate for Human Trials.
- Press release article from: PR Newswire August 25, 2003 700+ words
...IAVI). The vaccine candidate, named HIVA...human trials of the vaccine candidate already have been...preventive AIDS vaccine candidate that the MCC has...government's National Institute of Allergy and...
- VaxGen Finalizes Commercial Rights To Anthrax Vaccine Candidate.
- Press release article from: PR Newswire October 13, 2003 700+ words
...recombinant anthrax vaccine candidate based on technology...contract from the National Institute of Allergy and...VaxGen's anthrax vaccine candidate is based on the...animal models. The vaccine candidate is composed of...
Source: HighBeam Research, X-ray analysis conducted on protein vaccine candidate for malaria.